PH Research, S.L. Report issue

For profit Phase 1 Phase 2
Founded: Madrid Spain (2012)
Status: No NME R&D (2012)

Organization Overview

First Clinical Trial
2013
NCT02382263
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

PH Research, S.L.

Active Ingredients

Drugs in Phase 2 Trials (2)

gemcitabine (gemzar) (1 trial)

paclitaxel (taxol) (1 trial)

Drugs in Phase 1 Trials (2)

avelumab (bavencio) (1 trial)

hyaluronidase (human recombinant) (Hylenex) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 1)

Pancreatic Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 4